Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Mar 22, 2021 11:42am
103 Views
Post# 32850314

RE:RE:RE:RE:Momentum...

RE:RE:RE:RE:Momentum...

That's it in a nutshell. We can argue about what's stopping them being members of that club (marketing, data, history, whatever) but that's the problem their program is not seen as legitimate yet.


SPCEO1 wrote: I did not see a version of the PR that did not have the NASH part, and I read the NASH part closely to see if there was anything new in it. As best I could tell, it was just a rehash of what we already knew. It is smart for them to keep emphasizing NASH until they are finally acknowleded as a member of the phase III NASH club by investors, as they should have been since the FDA told them to proceed with their phase III trial. So, I don't think it is possible to claim that this PR had much to do with it, but if it did, I am not going to complain about it. Any way the company can get formally recognized by investors as a legit member of the phase III NASH club is a good way. 
 

jfm1330 wrote: I said more certainty on the NASH phase III would push the stock price higher and that's what we got with the last PR. Still not the official confirmation, but almost. This stock will rise on real facts and news, not on rosy projections.

SPCEO1 wrote: DEspite the company's challenges in marketing the stock effectively, it seems some larger buyer has figured it out as we have and is working hard to establish a decent sized position in THTX. Chances are they will end up being very happy with that position as you are right, the momentum seems strong on all fronts at the moment. Legacy drug sales are picking up (hopefully that will be confirmed in the Q1 report), cancer hasn't had any setbacks we are aware of yet and NASH is in the home stretch for its phase III trial. 

FredTheVoice wrote: Every week we beat the 52 year-weekly high will be good,

The momentum is clearly in our favor.....

New very competent CEO.

Good sales....

Good news on two front: ONCOLOGY and NASH

And lots lots LOTS of money in pharma sector......merger and aquisition to come in the sector 

And....lets say.....every economists are actually lifting up the projection in % of the economy prospect for 2021.....

Vaccination is gaining traction and.........Biden is not a bad move.....

FTV.

 

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse